TRDA Fair Value — Entrada Therapeutics Inc

Biotechnology · Institutional-depth multi-model valuation on Equity Rank

Current Price
$7.60
Consensus Fair Value
$6.62
Margin of Safety
-12.9%

When does TRDA report earnings?

Entrada Therapeutics Inc (TRDA) is next scheduled to report earnings on Aug 5, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-1.16.

Heading into this report, the model's fair value estimate sits 12.9% above the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.

Earnings dates and estimates are sourced from third-party data and may change or lag. Informational only.

How TRDA's valuation models agree

Equity Rank computed model fair value for TRDA from 2 independent valuation methods with sufficient data. 1 place fair value above the current price of $7.60, and 1 place it below. The model-blended estimate lands at $6.62 — a model fair value differential of 12.9% below the current price under these model assumptions. The methods are evenly split, reflecting genuine dispersion in the estimate.

Models: FV above price
1
Models: FV below price
1
Models compared
2

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

TRDA fundamental profile

Equity Rank's fundamental strength composite scores TRDA at 33.7/100 (D, Weak), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved -8.6 pp.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About TRDA

Entrada Therapeutics Inc (TRDA) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Stocks in Biotechnology

JNJ · UNH · PFE · ABBV · MRK

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator